InflaRx Looks Ahead To Late 2023 Commercial Sales For COVID-19 Antibody
Gohibic Cleared Under EUA
Executive Summary
The price will be more expensive than prior COVID-19 antibodies, reflecting its target to critically ill patients who are hospitalized.